Clinical trials: PET/CT Imaging
Cholangiocarcinoma
Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study
To evaluate the feasibility and performance of coregistered 18F-FDG-PET/MRI in the staging of potentially respectable hilar cholangiocarcinoma.
- Trial name
- PET/MRCP (NCT00604266)
- Where
- Canada
- Sponsor
- University of Toronto
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Neural Crest Tumor, Neuroendocrine Tumors
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
The aim of this study is to evaluate the potential and feasibility of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neural crest and neuroendocrine tumors.
- Trial name
- NCT04258592
- Testing
- (18F)MFBG, PET/CT, Venous blood samples
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors .
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer
- Trial name
- NCT05541367
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Lymphoma
Diffusion-weighted Magnetic Resonance Imaging in Post Therapy Patients With Lymphoma
The goal of this study is to determine the feasibility of the diffusion weighted Magnetic Resonance Imaging in the evaluation of the treatment response in patients with malignant lymphoma.
- Trial name
- NCT03969381
- Testing
- diffusion weighted magnetic resonance image in lymphoma
- Volunteers
- 50 people
- Sponsor
- Assiut University
FDG PET, Mucosal Melanoma
The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma
This project will target patients with histopathologically diagnosed mucosal melanoma using [¹⁸F]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of [¹⁸F]FDG PET/CT imaging…
- Trial name
- NCT07506447
- Testing
- Telephone follow-up
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Liver Carcinoma
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
This is a single arm study to evaluate the safety and biodistribution of 18F-labeled RD2 PET/CT Imaging in patients with small liver carcinoma.
- Trial name
- NCT05681234
- Testing
- 18F-RD2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
- Trial name
- NCT01205321
- Testing
- Bombesin (68Ga) labeled (BAY86-7548)
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Lantheus Biosciences Ltd.
DLL3-expressing Tumors, PET / CT
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
- Conditions
- DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
- Trial name
- NCT07458906
- Testing
- Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT
Comparative Evaluation of Contrast-Enhanced MRI and FDG-PET/CT in Spinal Pathology: Image Quality and Short-Term Renal-Hematologic Safety
This prospective comparative observational study evaluates image quality characteristics and short-term physiological effects associated with contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron…
- Conditions
- Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT, Spinal Pathology
- Trial name
- NCT07640386
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cairo University
Breast Cancer, Breast Cancer Invasive
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Invasive, Breast Cancer in Situ
- Trial name
- BrIMA (NCT04999917)
- Testing
- high-resolution PET-CT specimen imaging.
- Where
- Belgium
- Volunteers
- 206 people
- Sponsor
- XEOS Medical
Inflammatory Bowel Disease
Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
The purpose of the study is to evaluate the PK, safety and tolerability of PF-06687234 and [124I]IB-PF-06687234 (simultaneously given) in subjects with moderate to severe Ulcerative Colitis or Crohn's Disease.
- Trial name
- NCT03414788
- Testing
- PF 06687234, [124I]IB PF 06687234
- Where
- United States
- Sponsor
- Pfizer
Systemic Amyloidosis
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and…
- Trial name
- NCT05968846
- Testing
- Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Myocardial Ischemia
Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA
Coronary artery disease results in narrowing of the blood vessels supplying oxygenated blood to the heart muscle. Diagnosis in patients with symptoms of chest pain is now quickly done with CT coronary angiography.
- Trial name
- NCT01520025
- Testing
- PET MPI imaging with 18F-Fluorodeoxyglucose
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Solid Tumors
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects.
- Trial name
- NCT07529002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Pioglitazone Decreases Visceral Fat Metabolism
Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the…
- Trial name
- NCT01819402
- Testing
- Pioglitazone vs Glimepiride
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kurume University
Hodgkin's Lymphoma
Whole-body MRI in Pediatric Hodgkin's Lymphoma
Background: The assessment of extent of disease (staging) and response to therapy (restaging) is performed with computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET scan) or integrated…
- Trial name
- NCT04005703
- Where
- 8 sites in Austria, Italy and 2 more
- Volunteers
- 75 people
- Sponsor
- UMC Utrecht
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteer, Malaria
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body.
- Trial name
- NCT07859800
- Testing
- 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer
Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
Breast carcinoma is the most frequent cancer in women, affecting an estimated 207,090 in 2010 leading to 39,840 cancer related deaths.
- Trial name
- NCT01659645
- Testing
- FACBC
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Emory University